Fat reducing medicine may cut alcohol intake, relapse, finds Swedish study

New York

Fighting obesity as well as liquor addiction will never be more easy if we go by a Swedish study that claims fat-reducing medicine could cut alcohol intake and even relapse.

Semaglutide, a medicine prescribed by doctors to overweight or obese patients, had been shown to reduce alcohol intake in rats in lab conditions.

The study conducted by Sahlgrenska University Hospital and the Swedish Brain Foundation, claims that the glucagon-like peptide1 receptor found in the drug has shown positive effects to tackle liquor addiction.

The researchers conducted tests on mice to examine the ability of Semaglutide to decrease alcohol intake and block relapse-like drinking.

Good news for tipplers visiting Himachal hill stations as bar timings extended till 1 am

It also tested the binding of fluorescently marked Semaglutide to nucleus accumbens (NAc) in both male and female rats which showed that it had a suppressive effect on alcohol-induced locomotor stimulation.

“This indicates that Semaglutide reduces alcohol drinking behaviours, possibly via a reduction in alcohol-induced reward and NAc-dependent mechanisms.

As Semaglutide also decreased body weight of alcohol-drinking rats of both sexes, upcoming trials should test the plausibility that it reduces alcohol intake and body weight in overweight AUD patients,” the study added.

Viral Today: This orangutan’s reaction shows motherly feelings are the same in all species

It is worth noting that Semaglutide is orally administered and first long-acting medicine that had been approved by drug authorities to treat obesity and type II diabetes.